Duloxetine treatment of major depressive episodes in the course of psychotic disorders: A case report

Pharmacopsychiatry

Volumn 39, Issue 3, 2006, Pages 109-111

  Zink, Mathias ^a,b   Knopf, U ^a   Mase, E ^a   Kuwilsky, A ^a   Deuschle, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; DULOXETINE; NORADRENALIN; QUETIAPINE; SEROTONIN; VALPROIC ACID;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CASE REPORT; CLINICAL FEATURE; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DRUG MECHANISM; FEMALE; HEART RATE; HUMAN; PRIORITY JOURNAL; PSYCHOSIS;

ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PERSONALITY INVENTORY; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THIOPHENES; TREATMENT OUTCOME;

EID: 33745131434     PISSN: 01763679     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-941484     Document Type: Article

References (24)

1. Addington D, Addington J, Atkinson M. A psychometric comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. Schizophr Res 1996; 19: 205-212
2. Addington D, Addington J, Maticka-Tyndale E, Joyce J. Reliability and validity of a depression rating scale for schizophrenics. Schizophr Res 1992; 6: 201-208
3. An der Heiden W, Könnecke R, Maurer K, Ropeter D, Haefner H. Depression in the long-term course of schizophrenia. Eur Arch Psychiatry Clin Neurosci 2005; 255: 174-184
4. Caccia S. Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinetics 2000; 38: 393-414
5. Detke MJ, Lu Y, Goldstein DJ, Hayes JR, Demitrack MA. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002; 63: 308-315
6. Deuschle M, Krumm B, Bindeballe N, Colla M, Hamann B, Lederbogen F, Gilles M, Heuser I. Open-label non-randomized versus double-blind randomized antidepressive treatment: what are the advantages of clinical decision over randomization. Pharmacopsychiatry 2004; 37: 299-302
7. Gaebel W, Janssen B, Riesbeck M. Modern treatment concepts in schizophrenia. Pharmacopsychiatry 2003; 36 Suppl. 3: S168S175
8. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004; 24: 389-399
9. Kohler CG, Lallart EA. Postpsychotic depression in schizophrenia patients. Curr Psychiatry Rep 2002; 4: 273-278
10. Kuo F, Gillespie TA, Kulanthaivel P, Lantz RJ, Ma TW, Nelson DL, Threlkeld PG, Wheeler WJ, Yi P, Zmijewski M. Synthesis and biological activity of some known and putative duloxetine metabolites. [Erratum appears in Bioorg Med Chem Lett. 2004 Oct 18;14(20):5233]. Bioorg Med Chem Lett 2004; 14: 3481-3486
11. Lantz RJ, Gillespie TA, Rash TJ, Kuo F, Skinner M, Kuan HY, Knadler MP. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metabol Disposition 2003; 31: 1142-1150
12. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, American Psychiatric Association, and Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004; 161: 1-56
13. Mallinckrodt CH, Raskin J, Wohlreich MM, Watkin JG, Detke MJ. The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials. BMC Psychiatry 2004; 4: 26-26
14. Mazeh D, Shahal B, Saraf R, Melamed Y. Venlafaxine for the treatment of depressive episode during the course of schizophrenia. J Clin Psychopharmacol 2004; 24: 653-655
15. McGlashan TH, Waltrip RW. 2nd. Postpsychotic depression. Am J Psychiatry 1991; 148: 545-547
16. Palmer BA, Pankratz S, Bostwick JM. The lifetime risk of suicide in schizophrenia. Arch Gen Psychiatry 2005; 62; 247-253
17. Preskorn SH. Duloxetine. J Psychiatr Pract 2004; 10: 375-385
18. Repo-Tiihonen E, Eloranta A, Hallikainen T, Tiihonen J. Effects of Venlafaxine treatment on clozapine plasma levels in schizophrenic patients. Neuropsychobiology 2005; 51: 173-176
19. Silver H. Selective serotonin re-uptake inhibitor augmentation in the treatment of negative symptoms of schizophrenia. Expert Op Pharmacother 2004; 5: 2053-2058
20. Siris SG. Diagnosis of secondary depression in schizophrenia: implications for DSM-IV. Schizophr Bull 1991; 17: 75-98
21. Skinner MH, Kuan HY, Pan A, Sathirakul K, Knadler MP, Gonzales CR, Yeo KP, Reddy S, Lim M, Ayan-Oshodi M, Wise SD. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Therapeutics 2003; 73: 170-177
22. Spina E, Avenoso A, Scordo MG, Ancione M, Madia A, Levita A. No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites. Ther Drug Monitoring 2001; 23: 675-678
23. Van de Kar LD, Rittenhouse PA, Li Q, Levy AD. Serotonergic regulation of renin and prolactin secretion. Beh Brain Res 1996; 73: 203-208
24. Zoccali R, Muscatello MR, Cedro C, Neri P, La Torre D, Spina E, Di Rosa AE, Meduri M. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 2004; 19: 71-76